Karsten E. Weber

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani et al. · The Lancet Oncology · 2017 · 2.1K citations

Medicine, Immunology, Oncology +14

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Martin Filipits, Margaretha Rudas, R. Jakesz et al. · Clinical Cancer Research · 2011 · 728 citations · Full text

Medicine, Cancer Biology, Oncology +17

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 694 citations

Medicine, Oncology, Pharmacology +16

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

Peter Dubsky, Jan C. Brase, R. Jakesz et al. · British Journal of Cancer · 2013 · 349 citations · Full text

Medicine, Endocrinology, Oncology +17

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Sibylle Loibl, Karsten E. Weber, Kirsten M. Timms et al. · Annals of Oncology · 2018 · 300 citations · Full text

Medicine, Oncology, Pharmacology +17